The modal daily dose of lurasidone for the combined therapy groups was 20 mg for 9.0% of patients, 40 mg for 11.5% of patients, 60 mg for 43.4% of patients, and 80 mg for 36.1% of patients Table 2.
The most common grade 3 4 non-haematological toxicities were fatigue (32.6% of patients; 10.1% of cycles), nausea (16.3% of patients; 4.5% of cycles), vomiting (16.3% of patients; 3.9% of cycles), and anorexia (14.0% of patients; 4.5% of cycles).
A calcium score of >0 (EBT+) was found in 55% of patients; 45% of patients had a 0 score (EBT−).
The survival of 1/3rd of patients on ICU for ≥5 days to hospital discharge suggests that 5-day trials of ICU in HM patients are unlikely to reliably distinguish between survivors and non-survivors.
Attendants accompanied 91.1% (348/382) of patients.
Secondly, documentation for diabetes related morbidities was found for only 1/3rd of patients.
Nearly 2/3rd of patients with dCCA who undergo surgery have involvement of lymph nodes [ 21].
Overall, 24.5 % of patients received 6 ± 4 units.
CT scans were positive in 82 % of patients and 18F-FDG-PET-CT in 98 % of patients [85].
In the week ending 18 January, 92.4% of patients were admitted, transferred or discharged within the four-hour limit.
SPA occurred in 31.5% of patients [11].
